Hematologic Malignancies

Once-Weekly Carfilzomib for Patients with Relapsed or Refractory Multiple Myeloma Improves Progression-Free Survival

Walter Alexander

2018 EHA Congress Highlights, Multiple Myeloma

Once-weekly carfilzomib (Kyprolis) therapy at a higher dose significantly improved progression-free survival (PFS) and reduced the risk of disease progression or death compared with twice-weekly carfilzomib in patients with relapsed or refractory multiple myeloma. The overall safety profile for both regimens in the randomized phase 3 ARROW clinical trial were similar, said co-lead investigator María-Victoria Mateos, MD, PhD, Director, Myeloma Unit, University Hospital Salamanca-IBSAL, Spain, at the 2018 European Hematology Association Congress. [ Read More ]

Pomalidomide Added to the Regimen in First Relapse Extends PFS in Multiple Myeloma

Wayne Kuznar

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO 2018 Highlights - Clinical Trials, Multiple Myeloma

Chicago, IL—The triplet regimen of pomalidomide (Pomalyst), bortezomib (Velcade), and low-dose dexamethasone (PVd) significantly extended progression-free survival (PFS) compared with the doublet of bortezomib plus dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma who had previously received lenalidomide [ Read More ]

Nelarabine Therapy Up Front Boosts Survival in T-Cell Leukemia and Lymphoma

Phoebe Starr

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO 2018 Highlights - Leukemia

Chicago, IL—Moving nelarabine (Arranon), a T-cell–specific drug, up front combined with backbone chemotherapy (ie, COG-augmented Berlin-Frankfurt-Münster [aBFM]) improved survival by approximately 10% in the largest-­ever randomized clinical trial enrolling newly diagnosed children and young adults with T-cell acute lymphoblastic leukemia [ Read More ]

Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma

Wayne Kuznar

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO 2018 Highlights - Immunotherapy, Multiple Myeloma

Chicago, IL—The second-generation chimeric antigen receptor (CAR) T-cell therapy bb2121, engineered to target B-cell maturation antigen (BCMA), a protein on the surface of certain myeloma cells, displayed continuing efficacy and safety in an update of a phase 1 clinical trial [ Read More ]

Palliative Care Use Dismal Among Patients with Hematologic Malignancies

ASH 2017, Multiple Myeloma, Palliative Care

Atlanta, GA—The largest-ever analysis of palliative care trends has found the use of palliative care services to be sporadic at best among patients with hematologic malignancies. According to the review of approximately 300,000 patients by Sikander Ailawadhi, MD, Oncologist, Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, and colleagues, there was also significant heterogeneity in practice patterns across all characteristics studied. [ Read More ]

Stem-Cell Transplant in Multiple Myeloma Associated with Increased Healthcare Utilization and Costs

Chase Doyle

Leukemia, Multiple Myeloma

Atlanta, GA—A recent analysis of US administrative claims data showed that stem-cell transplantation (SCT) is associated with increased healthcare resource utilization and costs compared with matched controls. According to data presented at 2017 ASH, patients who underwent SCT had, on average, >$114,000 increase in healthcare costs compared with age-, sex-, and comorbidity-matched patients with multiple myeloma who did not undergo SCT. [ Read More ]